Pharmaceuticals Analysts, along with Dr. Raymond Wang, discuss Zevra Therapeutics (ZVRA)’ FDA approved Miplyffa, treatment for Niemann-Pick Disease Type C (NPC) on an Analyst/Industry conference call to be held on November 21 at 12 pm.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA: